We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
-3.48%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$824M
AUM Growth
-$97.4M
Cap. Flow
+$20.5M
Cap. Flow %
2.49%
Top 10 Hldgs %
67.68%
Holding
37
New
9
Increased
2
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
LENZ
LENZ Therapeutics
LENZ
+$40.1M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$26.5M
3
GHRS icon
GH Research
GHRS
+$26.1M
4
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$23.4M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$19.2M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$94M
2
TRIL
Trillium Therapeutics Inc.
TRIL
+$19.2M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$13.2M
4
ACET icon
Adicet Bio
ACET
+$10.4M
5
APTO
Aptose Biosciences, Inc.
APTO
+$9.59M

Sector Composition

Rank Sector Weight
1 Healthcare 91.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HARP
26
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$7.1M 0.86%
+51,201
New +$9.77M
ATXS
27
DELISTED
Astria Therapeutics
ATXS
$6.82M 0.83%
+539,000
New +$7M
ACET icon
28
Adicet Bio
ACET
$85.2M
$1.89M 0.23%
11,481
-51,019
-82% -$10.4M
VRDN icon
29
Viridian Therapeutics
VRDN
$2.09B
$357K 0.04%
19,495
– –
EYPT icon
30
EyePoint Inc
EYPT
$1.03B
– –
-700,000
Closed -$7.11M
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-591,782
Closed -$13.2M
SPRY icon
32
ARS Pharmaceuticals
SPRY
$509M
– –
-85,000
Closed -$3.71M
TNGX icon
33
Tango Therapeutics
TNGX
$4.43B
– –
-500,000
Closed -$5.56M
TSHA icon
34
Taysha Gene Therapies
TSHA
$1.68B
– –
-120,649
Closed -$2.45M
APTO
35
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-3,568
Closed -$9.59M
MTCR
36
DELISTED
Metacrine, Inc. Common Stock
MTCR
– –
-680,000
Closed -$4.22M
CNST
37
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-4,016,873
Closed -$94M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q2 2021 Portfolio in Review

As of Q2 2021, VR Adviser held 37 positions worth $824M, down 11% from $922M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

VR Adviser's Q2 2021 filing shows 9 new, 2 increased, 6 reduced and 8 closed positions. Its largest new stake was LENZ Therapeutics: 230,374 shares worth $49.6M. The largest sale was Constellation Pharmaceuticals, Inc., an estimated $94M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier.

  • VR Adviser's largest Q2 2021 buy was LENZ Therapeutics: 230,374 shares worth $49.6M.
  • VR Adviser added most to Aclaris Therapeutics in Q2 2021, an estimated $19.2M increase.
  • VR Adviser's biggest Q2 2021 reduction was Trillium Therapeutics Inc., cutting an estimated $19.2M.
  • VR Adviser fully exited Constellation Pharmaceuticals, Inc. in Q2 2021, selling an estimated $94M.
  • VR Adviser's ten largest holdings make up 68% of its $824M portfolio in Q2 2021.
  • VR Adviser opened 9 new positions and closed 8 in Q2 2021.
  • VR Adviser's portfolio value fell 11% quarter-over-quarter to $824M.

Based on VR Adviser's 13F filing for Q2 2021, filed 13 Aug 2021.